OpGen (NASDAQ:OPGN) Coverage Initiated at StockNews.com

Analysts at StockNews.com started coverage on shares of OpGen (NASDAQ:OPGNGet Rating) in a note issued to investors on Wednesday. The firm set a “sell” rating on the medical research company’s stock.

A number of other equities research analysts also recently weighed in on OPGN. Alliance Global Partners downgraded OpGen to a “neutral” rating in a report on Tuesday, July 19th. HC Wainwright reiterated a “buy” rating and issued a $3.00 target price on shares of OpGen in a report on Friday, June 10th.

OpGen Price Performance

Shares of OPGN opened at $0.43 on Wednesday. OpGen has a 1 year low of $0.31 and a 1 year high of $3.55. The company has a debt-to-equity ratio of 0.15, a current ratio of 1.40 and a quick ratio of 1.32. The company has a market capitalization of $20.78 million, a price-to-earnings ratio of -0.54 and a beta of -0.37. The business has a 50-day moving average of $0.52 and a 200-day moving average of $0.58.

OpGen (NASDAQ:OPGNGet Rating) last issued its quarterly earnings data on Thursday, August 11th. The medical research company reported ($0.13) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.02. The company had revenue of $0.97 million during the quarter, compared to the consensus estimate of $1.00 million. OpGen had a negative return on equity of 75.61% and a negative net margin of 624.26%. As a group, equities research analysts anticipate that OpGen will post -0.55 earnings per share for the current year.

Institutional Investors Weigh In On OpGen

An institutional investor recently raised its position in OpGen stock. Arete Wealth Advisors LLC grew its position in shares of OpGen, Inc. (NASDAQ:OPGNGet Rating) by 70.0% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 85,000 shares of the medical research company’s stock after acquiring an additional 35,000 shares during the quarter. Arete Wealth Advisors LLC owned about 0.18% of OpGen worth $64,000 as of its most recent filing with the Securities & Exchange Commission. Institutional investors and hedge funds own 7.24% of the company’s stock.

OpGen Company Profile

(Get Rating)

OpGen, Inc, a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits.

Read More

Receive News & Ratings for OpGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OpGen and related companies with MarketBeat.com's FREE daily email newsletter.